dc.contributor.author |
Martínez, Evelyn |
dc.contributor.author |
Garin, Olatz |
dc.contributor.author |
Pardo Cladellas, Yolanda |
dc.contributor.author |
Fernández, Pablo |
dc.contributor.author |
Guix, Benjamin |
dc.contributor.author |
Gutiérrez, Cristina |
dc.contributor.author |
Boladeras, Ana |
dc.contributor.author |
Ferrer i Julià, Ferran |
dc.contributor.author |
Hernández, Tania |
dc.contributor.author |
Ayala, Adriana |
dc.contributor.author |
Egiguren, Mikel |
dc.contributor.author |
Fernández, Gema |
dc.contributor.author |
Muñoz, Víctor |
dc.contributor.author |
Macías Hernández, Víctor |
dc.contributor.author |
Pera, Joan |
dc.contributor.author |
Pont, Àngels |
dc.contributor.author |
Ferrer Forés, Maria Montserrat |
dc.contributor.author |
Guedea, Ferran |
dc.date |
2021 |
dc.identifier |
https://ddd.uab.cat/record/241071 |
dc.identifier |
urn:10.5114/jcb.2021.103580 |
dc.identifier |
urn:oai:ddd.uab.cat:241071 |
dc.identifier |
urn:pmcid:PMC8117716 |
dc.identifier |
urn:pmc-uid:8117716 |
dc.identifier |
urn:pmid:34025730 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:8117716 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Journal of Contemporary Brachytherapy ; Vol. 13 (february 2021), p. 1-11 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra, i la creació d'obres derivades, sempre que no sigui amb finalitats comercials i que es distribueixin sota la mateixa llicència que regula l'obra original. Cal que es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.subject |
Quality of life |
dc.subject |
Prostate cancer |
dc.subject |
External beam radiotherapy |
dc.subject |
High-dose-rate brachytherapy |
dc.title |
Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost : a prospective multicenter study |
dc.type |
Article |
dc.description.abstract |
Brachytherapy (BT) and external beam radiation therapy (EBRT) are effective treatments for high-risk prostate cancer (PCa). However, the impact of these treatments on health-related quality of life (HRQL) remains unclear. In this study, we compared EBRT alone with EBRT plus a boost with high-dose rate (HDR)-BT to determine the impact on HRQL in patients with high-risk PCa. Prospective, multicenter study comparing patients with high-risk PCa treated with EBRT alone or EBRT + HDR-BT from 2004 to 2006. HRQL was assessed at baseline (pre-treatment) and periodically over the 5-year follow-up, using the SF-36 (v.2), EPIC, and FACT-G and FACT-P questionnaires. A total of 129 patients were included in the study, of these, 41 received EBRT alone and 88 EBRT + HDR-BT. All patients received hormonotherapy. Baseline clinical characteristics were similar, except for a slightly higher mean number of comorbidities in the EBRT group. During follow-up, the only significant between-group difference was a greater worsening on EPIC hormonal domain in the EBRT alone group (p = 0.028). There were no significant differences in time and interaction of treatment in SF-36, and FACT-G and FACT-P questionnaires or EPIC urinary incontinence, urinary irritative-obstructive, and bowel and sexual domains over the 5-year follow-up. Oncological outcomes were similar in both groups. After five years of follow-up, EBRT alone or combined with HDR-BT boost had a similar impact on HRQL in patients with high-risk localized PCa. However, patients in the EBRT alone group experienced greater worsening of hormonal domain according to EPIC questionnaire. |